Radiomics applied to lung cancer: A review

Translational Cancer Research

Volumn 5, Issue 4, 2016, Pages 398-409

  Scrivener, Madeleine ^a   de Jong, Evelyn E C ^b   van Timmeren, Janna E ^b   Pieters, Thierry ^a   Ghaye, Benoît ^a   Geets, Xavier ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Imaging; Lung cancer; Radiomics; Theragnostic

Indexed keywords

CANCER CLASSIFICATION; CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; HUMAN; IMAGE PROCESSING; IMAGE SEGMENTATION; LUNG CANCER; META ANALYSIS (TOPIC); ONCOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; RADIOMICS; REVIEW; TUMOR VOLUME; VALIDATION PROCESS; WORKFLOW;

EID: 84983288387     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.21037/tcr.2016.06.18     Document Type: Review

References (51)

1. Available online: https://cancerstatisticscenter.cancer.org
2. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-6.
3. Coroller TP, Grossmann P, Hou Y, et al. CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother Oncol 2015;114:345-50.
4. Fried DV, Tucker SL, Zhou S, et al. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014;90:834-42.
5. Carvalho S, Leijenaar RT, Velazquez ER, et al. Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol 2013;52:1398-404.
6. Cook GJ, O'Brien ME, Siddique M, et al. Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis. Radiology 2015;276:883-93.
7. Cook GJ, Yip C, Siddique M, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med 2013;54:19-26.
8. Balagurunathan Y, Gu Y, Wang H, et al. Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. Transl Oncol 2014;7:72-87.
9. Kumar V, Gu Y, Basu S, et al. Radiomics: the process and the challenges. Magn Reson Imaging 2012;30:1234-48.
10. Velazquez ER, Parmar C, Jermoumi M, et al. Volumetric CT-based segmentation of NSCLC using 3D-Slicer. Sci Rep 2013;3:3529.
11. Hatt M, Cheze-le Rest C, van Baardwijk A, et al. Impact of tumor size and tracer uptake heterogeneity in (18) F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med 2011;52:1690-7.
12. Parmar C, Rios Velazquez E, Leijenaar R, et al. Robust Radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One 2014;9:e102107.
13. Cheebsumon P, Boellaard R, deRuysscher D, et al. Assessment of tumour size in PET/CT lung cancer studies: PET-and CT-based methods compared to pathology. EJNMMI Res 2012;2:56.
14. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the Performance of Prediction Models. Epidemiology 2010;21:128-38.
15. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
16. Coroller TP, Agrawal V, Narayan V, et al. Radiomic phenotype features predict pathological response in nonsmall cell lung cancer. Radiother Oncol 2016;119:480-6.
17. Fried DV, Mawlawi O, Zhang L, et al. Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors. Radiology 2016;278:214-22.
18. Desseroit MC, Visvikis D, Tixier F, et al. Development of a nomogram combining clinical staging with F-FDG PET/CT image features in non-small-cell lung cancer stage I-III. Eur J Nucl Med Mol Imaging 2016;43:1477-85.
19. Carvalho S, Leijenaar RT, Troost EG, et al. Early variation of FDG-PET radiomics features in NSCLC is related to overall survival -the "delta radiomics" concept. Radiother Oncol 2016;118 Supplement 1:S20-S21.
20. Lovinfosse P, Janvary ZL, Coucke P, et al. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy. Eur J Nucl Med Mol Imaging 2016;43:1453-60.
21. Mattonen SA, Palma DA, Johnson C, et al. Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy for Lung Cancer: Physician Performance Versus Radiomic Assessment. Int J Radiat Oncol Biol Phys 2016;94:1121-8.
22. Mattonen SA, Tetar S, Palma DA, et al. Imaging texture analysis for automated prediction of lung cancer recurrence after stereotactic radiotherapy. J Med Imaging (Bellingham) 2015;2:041010.
23. Cunliffe A, Armato SG 3rd, Castillo R, et al. Lung texture in serial thoracic computed tomography scans: correlation of radiomics-based features with radiation therapy dose and radiation pneumonitis development. Int J Radiat Oncol Biol Phys 2015;91:1048-56.
24. Ganeshan B, Panayiotou E, Burnand K, et al. Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival. Eur Radiol 2012;22:796-802.
25. Dhara AK, Mukhopadhyay S, Dutta A, et al. A Combination of Shape and Texture Features for Classification of Pulmonary Nodules in Lung CT Images. J Digit Imaging 2016;29:466-75.
26. Dilger SK, Uthoff J, Judisch A, et al. Improved pulmonary nodule classification utilizing quantitative lung parenchyma features. J Med Imaging (Bellingham) 2015;2:041004.
27. Parmar C, Leijenaar RT, Grossmann P, et al. Radiomic feature clusters and prognostic signatures specific for Lung and Head & Neck cancer. Sci Rep 2015;5:11044.
28. Leijenaar RT, Carvalho S, Velazquez ER, et al. Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol 2013;52:1391-7.
29. Oliver JA, Budzevich M, Zhang GG, et al. Variability of Image Features Computed from Conventional and Respiratory-Gated PET/CT Images of Lung Cancer. Transl Oncol 2015;8:524-34.
30. Yip S, McCall K, Aristophanous M, et al. Comparison of Texture Features Derived from Static and Respiratory-Gated PET Images in Non-Small Cell Lung Cancer. PloS One 2014;9:e115510.
31. Yoon HJ, Sohn I, Cho JH, et al. Decoding Tumor Phenotypes for ALK, ROS1, and RET Fusions in Lung Adenocarcinoma Using a Radiomics Approach. Medicine (Baltimore) 2015;94:e1753.
32. Panth KM, Leijenaar RT, Carvalho S, et al. Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells. Radiother Oncol 2015;116:462-6.
33. Leijenaar RT, Carvalho S, Hoebers FJ, et al. External validation of a prognostic CT-based radiomic signature in oropharyngeal squamous cell carcinoma. Acta Oncol 2015;54:1423-9.
34. van Gómez López O, García Vicente AM, HongueroMartínez AF, et al. Heterogeneity in [18F] fluorodeoxyglucose positron emission tomography/ computed tomography of non-small cell lung carcinoma and its relationship to metabolic parameters and pathologic staging. Mol Imaging 2014;13.
35. Carvalho S, Leijenaar RT, Troost EG, et al. OC-0205: Prognostic value of pre-RT PET metrics of lymph nodes vs. primary tumor in NSCLC: which holds more information? Radiother Oncol 2015;115 Supplement 1:S103-S104.
36. Zegers CM, van Elmpt W, Reymen B, et al. In Vivo Quantification of Hypoxic and Metabolic Status of NSCLC Tumors Using [18F]HX4 and [18F]FDG-PET/ CT Imaging. Clin Cancer Res 2014;20:6389-97.
37. Zegers CM, van Elmpt W, Wierts R, et al. Hypoxia imaging with [18F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol 2013;109:58-64.
38. Dubois LJ, Lieuwes NG, Janssen MH, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A 2011;108:14620-5.
39. van Loon J, Janssen MH, Ollers M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging 2010;37:1663-8.
40. Galavis PE, Hollensen C, Jallow N, et al. Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters. Acta Oncol 2010;49:1012-6.
41. Fave X, Mackin D, Yang J, et al. Can radiomics features be reproducibly measured from CBCT images for patients with non-small cell lung cancer? Med Phys 2015;42:6784-97.
42. Leijenaar RT, Nalbantov G, Carvalho S, et al. The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Sci Rep 2015;5:11075.
43. Balagurunathan Y, Kumar V, Gu Y, et al. Test-retest reproducibility analysis of lung CT image features. J Digit Imaging 2014;27:805-23.
44. Nagel CC, Bosmans G, Dekker AL, et al. Phased attenuation correction in respiration correlated computed tomography/positron emitted tomography. Med Phys 2006;33:1840-7.
45. van Elmpt W, Hamill J, Jones J, et al. Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours. Eur J Nucl Med Mol Imaging 2011;38:843-55.
46. Liu C, Alessio A, Pierce L, et al. Quiescent period respiratory gating for PET/CT. Med Phys 2010;37:5037-43.
47. Dawood M, Buther F, Jiang X, et al. Respiratory motion correction in 3-D PET data with advanced optical flow algorithms. IEEE Trans Med Imaging 2008;27:1164-75.
48. Lambin P, van Stiphout RG, Starmans MH, et al. Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol 2013;10:27-40.
49. Lambin P, Roelofs E, Reymen B, et al. 'Rapid Learning health care in oncology' -an approach towards decision support systems enabling customised radiotherapy'. Radiother Oncol 2013;109:159-64.
50. Lambin P, Petit SF, Aerts HJ, et al. The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol 2010;96:145-52.
51. Lambin P, Zindler J, Vanneste B, et al. Modern clinical research: How rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta Oncol 2015;54:1289-300.